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Abstract
The real-time live fluorescent monitoring of surface AMPA receptors (AMPARs) could open new opportunities for drug
discovery and phenotypic screening concerning neuropsychiatric disorders. We have developed FORTIS, a tool based
on pH sensitivity capable of detecting subtle changes in surface AMPARs at a neuronal population level. The
expression of SEP-GluA1 or pHuji-GluA1 recombinant AMPAR subunits in mammalian neurons cultured in 96-well
plates enables surface AMPARs to be monitored with a microplate reader. Thus, FORTIS can register rapid changes in
surface AMPARs induced by drugs or genetic modifications without having to rely on conventional electrophysiology
or imaging. By combining FORTIS with pharmacological manipulations, basal surface AMPARs, and plasticity-like
changes can be monitored. We expect that employing FORTIS to screen for changes in surface AMPARs will accelerate
both neuroscience research and drug discovery.
Introduction
In the central nervous system (CNS), excitatory gluta-
matergic synapses control neurotransmission mediated by
ion flow through α-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid receptors (AMPARs). Regulating the
exo- and endocytosis of AMPAR is a critical aspect of
synaptic plasticity, influencing long-term potentiation
(LTP) and long-term depression (LTD) at excitatory
synapses. Consequently, it is now recognized that AMPARs
are crucial for many aspects of brain function, including
learning and memory1–5, and abnormal AMPAR trans-
mission has been implicated in cognitive impairment4,6–8.
Pharmacological and molecular manipulations can
enhance cognitive function in mice9–11, demonstrating that
improved synaptic function, including some forms of
synaptic plasticity, plays a critical role in cognitive
enhancement12–16. Indeed, there is evidence that boosting
AMPAR activity may be an efficient approach to modulate
synapses that undergo experience-dependent changes to
enhance cognition16–19. Given the importance of AMPARs
in brain function, there is a clear need to rapidly screen for
drugs and conditions that alter AMPAR expression and
function in physiologically relevant contexts.
Synaptic plasticity has for long been investigated using
primary cultures of neurons17,18,20,21. To date, approaches
to monitoring synaptic transmission and synaptic plasticity
have focused on both electrophysiology and the imaging of
individual dendritic spines. Both methods are well estab-
lished and supply considerable information regarding
synaptic function in a variety of conditions. Nevertheless,
such approaches are labor-intensive and low-throughput,
and they are not suited to the fast evaluation of drugs or
rapid phenotyping. In terms of drug screening and dis-
covery, many assays have been developed based on human
neuroblastoma cell lines22–26 representing an unlimited and
homogenous resource for high throughput screening.
Nonetheless, the pharmacological data obtained with
immortalized cells do not always reflect the compounds’
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desired clinical efficacy and safety27. The physiologically of
primary cells is a much more relevant cell model than
immortalized cell lines. Therefore, there has been an effort
in recent years to optimize the conditions of primary neu-
ronal cell culture, which will enable new screening assays to
be developed based on primary neuronal cultures28,29.
Here we have designed and validated FORTIS (FluOr-
escence Receptor TraffIcking Screening), an efficient
approach to label, monitor, and analyze synaptic efficacy
and plasticity in live neurons. Genetically encoded AMPAR
reporters are now available to selectively label surface
AMPARs with a high signal-to-background ratio in live
cells, enabling non-invasive, longitudinal monitoring of
synaptic efficacy and function. As such, we used viral
vectors to express recombinant AMPARs tagged with
super ecliptic pHluorin (SEP, green fluorescence), and we
engineered a new AMPAR subunit labeled with pHuji, pH-
sensitive red fluorescence30. We show that FORTIS can be
used in short-term and long-term experiments, allowing a
temporal characterization of agents that affect AMPAR
distribution. FORTIS is a versatile, fast, and cost-effective
tool, and we propose that it can be used as an initial step
for rapid phenotyping and drug discovery.
Materials and methods
All the experiments were approved by the committees
for ethical care and use of animals in experiments at Ben-
Gurion University of the Negev (b14764_30) and the
University of the Basque Country (M20/2016/001; M20/
2018/296; M20/2016/019).
Construct generation
The pHuji DNA sequence was amplified by PCR from
the Addgene plasmid 61556. The pHuji sequence was
introduced in-frame, downstream of the GluA1 signal
peptide (22 aa), using the Gibson Assembly® Master
Mix—Assembly (New England Biolabs, #E2611), and it
was subcloned into the pSinRep5 plasmid under the
control of the Sindbis subgeneric promoter.
Extracellular solutions
The solutions tested to determine the most suitable
solution for long-term monitoring while maintaining the
pH stable were (in μM): (A) 129 NaCl, 4 KCl, 4 CaCl2, 10
HEPES, 10 Glucose [pH 7.4]; (B) 129 NaCl, 4 KCl, 4
CaCl2, 25 HEPES, 10 Glucose [pH 7.4]; (C) 129 NaCl, 4
KCl, 4 CaCl2, 18 NaHCO3, 10 HEPES, 10 Glucose [pH
7.4]; (D) 129 NaCl, 4 KCl, 4 CaCl2, 18 NaHCO3, 25
HEPES, 10 Glucose [pH 7.4].
Fluorescence monitoring with a microplate reader
Ninety-six-well plates containing neurons maintained
for 14–22 DIV were transferred to a Spark Multimode
Microplate reader (Tecan). This system offers complete
environmental control for live cells, with temperature,
CO2, and humidity control, thereby guaranteeing neuro-
nal survival for at least 50 h. After obtaining a baseline
recording (5–60min), the cultures were subjected to the
experimental treatments. Fluorescence readings were
obtained with a 475/535 nm (Ex−Em) excitation/emission
filter for GFPs or a 485/20-535/25 filter for red fluorescent
proteins. The data were post-processed using Magellan
software (Tecan).
Induction of chemical LTP and LTD
For the FORTIS experiments, dissociated primary neu-
rons (20–24 DIV) were grown in glass-bottomed, black, 96-
well plates (Cellvis, P96-1.5H-N). After replacing the cul-
ture medium with the extracellular solution (in μM: 129
NaCl, 4 KCl, 4 CaCl2, 18 NaHCO3, 10 HEPES, 10 glucose
[pH 7.4]), the experiments were performed at 24 or 37 °C,
with the [CO2] set at 5%. Baseline fluorescence intensity
measurements were first obtained, after which cLTP was
induced based on a protocol described previously31,
injecting glycine to each well (final concentration of
30–500 μM) unless otherwise indicated. Briefly, neurons
were treated for 5min at 37 °C and in 5% CO2 with an
extracellular solution containing NMDA (20 or 50 μM)
along with 10 µM glycine, followed by incubation in an
extracellular solution containing 4mM MgCl2. The con-
trols were treated with an extracellular solution alone.
Statistical analysis
We did not carry out a sample size calculation or ran-
domization of the samples. We performed some of the
analysis blindly (e.g., spine density, image analysis). Cul-
tures with a deteriorated general health were excluded
from the study. All statistical analyses were performed
using GraphPad Prism (version 8.00, GraphPad Software,
La Jolla, CA, USA). Datasets were scrutinized for normal
distribution using the Kolmogorov–Smirnov normality test
in order to choose the appropriate parametric or non-
parametric analysis. Data are presented as mean ± standard
error of the mean (SEM) of the n (number of cells, cul-
tures) indicated in each legend. All the experiments were
repeated at least three times, and the presented data are the
combination of the results of all the repetitions. Statistical
tests (including the p values) used for each comparison are
detailed in the figures and the figure legends.
The rest of the methods can be found in the Supple-
mentary Material.
Results
Optimization of the culture conditions for 96-well plate
screening
Primary neurons form physiological synaptic networks,
cultures, providing an experimentally accessible system to
study synaptic function32. Thus, primary neurons remain
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the gold standard source material for in vitro neurobio-
logical research. We observed that the general appearance
of neurons growing in 96-well plates was similar to that of
neurons growing in 24-well plates (Fig. 1a, b). The aim
was to have enough neurons to ensure their survival and
limit cell death33 while obtaining a large population of
synapses34 to facilitate synaptic plasticity35. As such, we
plated 15,000–60,000 cells/well onto black-walled, thin-
bottomed 96-well plates in 100 μl of medium/well, and we
checked their viability under a brightfield microscope.
Plating 40,000 or 60,000 cells per well yielded very con-
fluent cultures with a large proportion of viable neurons,
while seeding 80,000 cells per well resulted in neuronal
death (data not shown). Under these conditions
(40,000–60,000 cells per well), neurons in 96-well plates
were viable for 3–4 weeks in culture, allowing synapto-
genesis and synaptic maturation to occur. Accordingly,
the dendritic spine density in cultures grown in a 96-well
plate under these conditions was similar to that of cul-
tures growing in 24-well plates (Fig. 1c). The physiological
health of the neurons was also normal, as evaluated with
calcium imaging (see Suppl. Results).
We then set out to determine the optimal conditions for
detecting changes in fluorescence with the microplate
reader. To overcome the susceptibility of primary neurons
to transfection toxicity and their inherent low transfection
efficiency36, we used DH(26S), a neurotropic strain of
Sindbis virus and a member of the alphaviruses that
preferentially infects neurons over glia37. In our cultures,
neurons represent approximately half of the cells, as
witnessed by quantifying the NeuN and DAPI labeling of
cells (Suppl. Fig. 1a). We first wondered if a microplate
reader could detect changes in the proportion of infected
neurons. Indeed, we observed a linear correlation between
the proportion of infected neurons and the fluorescence
detected (FEGFP: Suppl. Fig. 1b). Based on fluorescence-
activated cell sorting (FACS) of infected cultures, we
calculated that our purified virus titer was 1.66 × 108
transducing units per ml (TU/ml). By direct visualization
of fluorescent images, we confirmed that the diluted virus
(3.3 × 106 TU/ml) infected a large proportion of the
neurons (Suppl. Fig. 1c)37 and that the virus is neurotoxic
at concentrations above 4.0 × 106 TU/ml (data not
shown)38. Through FACS, Sindbis virus (3.3 × 106 TU/ml)
was seen to infect approximately 50% of the cells in the
culture regardless of the number of cells seeded (Suppl.
Fig. 1d), a number that corresponded to the actual pro-
portion of the neurons in the culture (Suppl. Fig. 1a). In
addition, irrespective of the virus’s titer (3.3 × 105–3.3 ×
106 TU/ml), the fluorescence distribution of EGFP+
(enhanced green fluorescent protein) cells was similar
(Suppl. Fig. 1e). Hence, practically all neurons in a given
culture appear to be infected and the virus achieves
maximal infection at a titer of 3.3 × 106 TU/ml.
Changes in surface GluA1 fluorescence can be detected
with a microplate reader
To monitor the real-time fluorescence of live neurons, we
first determined the optimal culture medium for scanning.
Neurobasal medium alone exhibits a high level of auto-
fluorescence in the green channel (Ex−Em 485/20–535/
25 nm), regardless of the presence of serum (fetal bovine
serum; FBS), cells, or phenol-red (Suppl. Fig. 1f), impeding
the monitoring of GFPs. By contrast, a standard extra-
cellular solution has an autofluorescence similar to water
(Suppl. Fig. 1f). Thus, the extracellular solution can be used
to monitor fluorescence when using GFPs while keeping
neurons alive over a few hours. Ideally, it should be possible
to monitor surface AMPARs for periods of hours or even
days. As phenol red-free medium displays fluorescence in
the red channel (Ex−Em 560/10–610/20) identical to an
extracellular solution or water (Suppl. Fig. 1g), it might be
suitable for long-term measurements. Indeed, when tdTo-
mato using Sindbis virus was expressed in neurons main-
tained in phenol red-free medium, increased expression of
tdTomato could be detected with a microplate reader 6 h
after infection37 (Suppl. Fig. 1h), confirming the feasibility
for long-term monitoring using red fluorescent proteins.
Fluorescent proteins with pH-sensitive fluorophores are
quenched in endosomes and are valuable tools to detect
protein exocytosis and endocytosis in real time39,40. We
infected neurons with the GluA1 subunit of AMPAR fused
to SEP at its N-terminal. For long-term surface GluA1
monitoring, we replaced SEP with pHuji, a red fluorescent
protein with a pH sensitivity that approaches SEP41,
creating the new fusion protein, pHuji-GluA1. We used
Sindbis viral vectors to express both SEP-GluA1 and
pHuji-GluA1 in neurons (Fig. 1d, e), enabling the selective
labeling of surface receptors in culture30,42. Due to the pH-
dependent visibility of both recombinant proteins, live
neurons expressing SEP-GluA1 generally show weak
fluorescence under basal conditions. Yet, in fixed infected
neurons, SEP/pHuji-GluA1 can be seen in the soma
(excluding the nucleus), dendrites, and spines (Fig. 1d, e).
This fluorescence co-localized with the immunostaining of
GluA1 antibodies and a band representing SEP/pHuji-
GluA1 protein can be seen in western blots, in which SEP-
GluA1 and pHuji-GluA1 protein bands were evident when
probed with a GluA1 antibody, in addition to the endo-
genous protein (Fig. 1f). We also found that endogenous
GluA1 expression increased by approximately 50% in
infected cultures and that in infected cultures, the amount
of SEP/pHuji-GluA1 expressed was equivalent to the
amount of endogenous GluA1 (Fig. 1g). Together the total
amount of GluA1 (endogenous plus recombinant)
increased more than threefold in infected neurons (Fig. 1g),
reflecting the GluA1 overexpression in our system.
As FORTIS depends on the fluorescence emitted by
pH-dependent proteins, we tested different buffers for
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their ability to maintain a given pH for extended periods
(up to 16 h) under controlled CO2 (5%) and temperature
(24 or 37 °C) conditions in the plate reader. As expected,
the addition of NaHCO3 to the extracellular solution was
critical to maintaining the solution at a pH of 7.4. By
contrast, solutions lacking NaHCO3 decreased their pH to
Fig. 1 (See legend on next page.)
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acidic values (Suppl. Fig. 2a). The signal-to-background
ratio (Finfected/Funinfected) was lower for pHuji-GluA1
(~1.40) than SEP-GluA1 (~1.80: Suppl. Fig. 2b). How-
ever, the coefficient of variation at an extracellular pH 7.4
was lower for pHuji-GluA1 (~7%) than for SEP-GluA1
(~15%), implying a lower variability in fluorescence
between cultures expressing pHuji-GluA1 (see frequency
plots in Suppl. Fig. 2c). As expected, SEP/pHuji-GluA1
fluorescence was quenched in an acidic buffer (pH
5.5)43,44, whereas it was enhanced following treatment
with ammonium chloride (NH4Cl, 25–50mM: Fig. 1h–i).
Thus, a microplate reader can reliably detect changes in
the SEP/pHuji-GluA1 fluorescence provoked by changes
in the extracellular solution. Indeed, the dynamic range of
SEP-GluA1 under our experimental conditions was 3.42
(±0.50), while that of pHuji-GluA1 was 2.68 (±0.12:
Fig. 1i). Thus, these AMPAR reporters generate a strong
signal with a high signal-to-background ratio.
FORTIS can detect increases in GluA1 fluorescence attributed
to chemical LTP induction
A substantial proportion of AMPARs are located within
the cytoplasm of neurons, including dendrites and den-
dritic spines45,46. We reasoned that since most of the
SEP-GluA1 signal is on dendritic spines30 and given that
LTP-related increases in SEP-GluA1 can be detected in
individual spines30,47,48, we should be able to see chemical
LTP (cLTP)-like increases in SEP/pHuji-GluA1 fluores-
cence at the population level with a microplate reader.
To ensure that our protocol indeed induces cLTP, we
conducted a series of experiments employing various
approaches. We induced cLTP in primary cultures with
glycine (100 µM) while neurons were incubated in an
Mg2+-free extracellular solution to prevent Mg2+ from
blocking the activity of NMDARs49,50. As expected, we
observed a significant increase in active (Thr286‐phos-
phorylated) CaMKII51,52 and the phosphorylation of its
substrate GluA1 at Ser831, a CaMKII/PKC site53,54 (Suppl.
Fig. 3c). These phosphorylation events were blocked by
exposure to the NMDAR inhibitor APV (50 μM: Suppl.
Fig. 3e). The same protocol significantly increased the
labeling of active CaMKII51,52 in dendritic spines (Suppl.
Fig. 3d) and enlarged spine heads20,30,55 (Fig. 1j–l). Fluor-
escence microscopy also demonstrated an apparent rise in
SEP/pHuji-GluA1 fluorescence after cLTP induction
(Fig. 1m, n). Hence, these experiments validated our cLTP
protocol and indicated that this manipulation could
enhance the SEP/pHuji-GluA1 fluorescence detected by
FORTIS.
We then employed a dynamic assay to record surface
AMPAR fluorescence in each well at multiple time points.
By normalizing readings after drug addition to the basal
readings (ΔF/F0), the resulting ratios reflect the increase
(%) in the surface incorporation of AMPARs during
the assay period. We monitored SEP-GluA1 fluorescence
following cLTP induction as LTP is accompanied by
the rapid insertion of AMPARs and enhanced clustering
of AMPARs at the surface of dendritic membranes56.
(see figure on previous page)
Fig. 1 Optimization of culture conditions and characteristics of SEP- and pHuji-GluA1 AMPAR subunits. a Brightfield images (×20) of
hippocampal neurons (20 DIV) cultured in 24- or 96-well plates. b Confocal projection images (×10) of hippocampal neurons expressing EGFP that
were used for spine counting. c Left, Representative examples of confocal projection images (×63) of hippocampal neuron dendrites expressing EGFP
growing in 24- or 96-well plates. Right, Quantification of the dendritic spines on hippocampal neurons growing in 24- or 96-well plates performed
with Imaris software: N represents the number of cells, and the p value was determined according to the two-sided Mann–Whitney test. d–e Left, a
confocal projection image (×40) of fixed hippocampal neurons in a 96-well plate expressing SEP-GluA1 or pHuji-GluA1. Right, a high magnification
(×60, digital zoom 3) projection image of dendrites expressing SEP-GluA1 or pHuji-GluA1 immunostained with an anti-GluA1 antibody (for SEP-GluA1
in red using an Alexa 594-conjugated secondary antibody, for pHuji-GluA1 in green, using an Alexa 488-conjugated secondary antibody), to show the
co-localization of the recombinant and endogenous GluA1 proteins. f Western blot showing the endogenous and recombinant GluA1 (SEP-GluA1
and pHuji-GluA1). In color, the lysate of infected neurons was loaded onto a polyacrylamide gel and viewed with a gel documentation system. A
band of the corresponding color can be seen at the expected size. g Quantification of the endogenous and the recombinant GluA1 proteins.
N represents the number of cultures, and the p values were determined with a Mann–Whitney test. h Heat maps showing the changes in SEP/pHuji-
GluA1 as a function of pH and after the addition of ammonium chloride (NH4Cl). Each square represents the relative fluorescence in a single well
(culture). i Real-time measurements of SEP/pHuji-GluA1 starting at pH 7.4 (time 0), after which the pH was reduced to 5.5 and then increased back to
7.3 and 7.9 with increasing concentrations of NH4Cl. j Representative projections of dendrites from hippocampal neurons expressing EGFP and
treated with glycine (100 μM) to induce cLTP. The neurons were fixed for 20 min after induction, and the cultures were immunostained with the
PSD95 antibody (using an Alexa 594-conjugated secondary antibody). k Bar graph showing the average PSD95 puncta area, where N represents the
number of neurons, and the p value was determined according to the two-sided Student’s t-test. l Cumulative frequency curves showing a shift to
the right in the PSD95 puncta size in glycine-treated neurons, with the number of PSD95 puncta. m, n Fluorescent images of hippocampal cultures
infected with pHuji-GluA1 or SEP-GluA1, both at baseline and immediately after treatment with glycine (100 μM). o A heat map of the changes in
SEP-GluA1 fluorescence (ΔF/F0, %) where each square represents a single hippocampal culture in a 96-well plate. After a 5-min baseline, cLTP was
induced by injecting glycine (as indicated by the arrow). The fluorescence was measured at 485/40–528/20 (Ex−Em) every 5 min for 1 h. The color
map represents the change in fluorescence 60 min after cLTP induction. p Changes in SEP-GluA1 fluorescence following cLTP induction. Each gray
line represents the ΔF/F0 in a single culture (well), while the black line with the green symbol represents the average of ΔF/F0 (normalized to the
average baseline of each culture) in the cultures treated with glycine (100 μM). The data are presented as the mean ± SEM.
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We replaced the medium of SEP/pHuji-GluA1-expressing
neurons (24–48 h after infection, DIV 20–24) with an
extracellular solution. After a baseline fluorescence
recording, we automatically added glycine at different
concentrations using the microplate reader’s injector. The
addition of glycine produced an immediate dose-
dependent increase in SEP-GluA1 fluorescence (Figs. 1o,
p and 2a, b) blocked by APV (Suppl. Fig. 3e), consistent
with data on LTP induced in slices and cultured cells57–60.
Hence, it appears that FORTIS not only detects popula-
tion changes in SEP-GluA1 fluorescence following cLTP
induction but can also detect subtle changes induced by
different doses of glycine. We observed a similar increase
in pHuji-GluA1 fluorescence (Suppl. Fig. 3f). In some
experiments, instead of monitoring recombinant GluA1
in live neurons, we immunostained the endogenous sur-
face and total GluA1 in fixed cultures (Suppl. Fig. 4a). We
observed with a microplate reader increases in the sur-
face/total GluA1 fluorescence ratio following exposure to
glycine (Suppl. Fig. 4b).
When we induced cLTP in cortical neuronal cultures, we
observed a similar dose–response to glycine (Fig. 2c). The
frequency distribution of the magnitude of ΔF/F0 was also
indistinguishable between hippocampal and cortical neu-
rons, showing that most cultures exhibited a 10–30%
increase in fluorescence following cLTP induction (100 μM
glycine: Fig. 2d). We then used a previously described
chemical stimulation protocol of forskolin plus rolipram
(F/R: 50 μM/0.1 μM) to provoke cLTP61–63. As with the
glycine protocol, F/R addition induced a significant increase
in SEP-GluA1 fluorescence (Fig. 2e), paralleled by a corre-
sponding rise in Ser845 (PKA site) GluA1 phosphoryla-
tion61,64 (Fig. 2e). To assess if FORTIS can be used to
evaluate plasticity in transgenic mice, we used hippocampal
cultures from mice overexpressing phosphatase and tensin
homolog (PTEN; Ptentg mice) that exhibit deficits in LTP65.
We observed a significantly smaller cLTP-related increase
in SEP-GluA1 fluorescence in cultures derived from Ptentg
mice (Fig. 2f, g). Hence, FORTIS may be used as part of the
phenotyping of transgenic mice.
FORTIS can detect decreases in surface AMPARs attributed to
chemical LTD induction
To establish the cLTD protocol for FORTIS, we first
confirmed that NMDAR stimulation is accompanied by
GluA1 dephosphorylation at Ser84566 (Fig. 3a–c). As
expected, this decrease in phosphorylation was blocked by
APV (50 µM, Fig. 3a, c)61. Crucially, the recombinant SEP-
GluA1 and pHuji-GluA1 showed similar depho-
sphorylation to the endogenous proteins (Fig. 3d, e). After
establishing the cLTD protocol, we induced cLTD in
cortical neurons by applying NMDA (20 or 50 μM) for
5 min31,67. We detected a significant decrease in SEP-
GluA1 fluorescence following this treatment, which was
stable for at least 2 h after applying NMDA (Fig. 3f, g). We
obtained similar results from hippocampal neurons
(Suppl. Fig. 4c), and thus FORTIS can be used with a
microplate reader to detect reductions in surface
AMPARs triggered by cLTD stimulation.
FORTIS can identify known cognitive enhancers
We tested our system with two drugs known to increase
the amount of AMPAR at synapses and enhance cognitive
function in rodents. The synthetic mimetic peptide of
the neural cell adhesion molecule (NCAM), FGLoop
(FGL), was explicitly engineered to mimic the functional
interaction between NCAM and the fibroblast growth
factor receptor (FGFR)18,68,69. FGL initiates a signaling
cascade that translates into persistent CaMKII activity and
facilitates the synaptic delivery of AMPARs during
synaptic plasticity16,18,70, and enhances learning and
memory in various experimental paradigms, supporting
the strong link between AMPAR activity and cognitive
enhancement18,71,72. We treated SEP-GluA1-expressing
neurons with FGL (10–200 μg/ml) and observed a
dose–response increase in SEP-GluA1 fluorescence 24 h
later, with the peak at 25 μg/ml (Fig. 4a, b). We also found
a dose-dependent increase in phospho-GluA1 with the
highest phosphorylation observed at 25 μg/ml (Fig. 4c, d),
consistent with observations in organotypic cultures18.
When the neurons were exposed to both FGL and TTX
(3 µM), the increase in SEP-GluA1 fluorescence in the
presence of FGL was abrogated (Fig. 4e, f). Hence FGL
appeared to require a neuronal activity for the delivery of
AMPARs to synapses. By contrast, the PI3K inhibitor had
no effect on FGL activity, further evidence that FGL does
not modulate AMPAR delivery via the PI3K pathway18
(Fig. 4e, f). Together, these findings suggest that FORTIS
can detect the effects of a drug known to facilitate
AMPAR surface delivery.
Conversely, we inhibited three signaling pathways
known to facilitate AMPAR trafficking in neurons
expressing pHuji-GluA1: the MAPK, PKC, and CaMKII
pathways18,73–75. Exposing the cells to PD98059 (25 µM),
a potent inhibitor of MAPK kinase (MEK)75, or cheler-
ythrine (5 µM), a general PKC inhibitor73,76, reduced
pHuji-GluA1 fluorescence over 50 h (Fig. 4g). Similarly,
the inhibition of CaMKII with KN93 (20 µM) 18,77 but not
exposure to its inactive derivative KN92 (20 μM) induced
a significant long-term decrease in pHuji-GluA1 (Fig. 4h).
These data suggest that FORTIS is sensitive and suffi-
ciently specific to detect changes in surface AMPARs
arising from well-established drugs with known effects on
AMPAR transmission.
Based on the current hypothesis regarding the mole-
cular basis of memory failure in Alzheimer’s disease (AD),
soluble assemblies of the amyloid-β peptide (Aβ) are
responsible for synaptic malfunctions that provoke a
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range of deficits from mild cognitive impairment to
dementia17,78–82. Indeed, Amyloid β (Aβ) induces
decreases in AMPAR efficacy indicative of synaptic
depression as an early AD event17,80,82,83. We first con-
firmed that FORTIS could detect Aβ-induced AMPAR
endocytosis, for which we used Aβ secreted by neurons
Fig. 2 (See legend on next page.)
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following the virally driven expression of a mutant form of
Amyloid precursor protein (App, human App with the
Swedish/London double mutation, Appswe/lnd-IRES-
EGFP, Fig. 5a, b)17. We replaced half of the culture
medium of neurons expressing either SEP-GluA1 or
pHuji-GluA1 with medium from neurons expressing
Appswe/lnd (final Aβ concentration: 10.29 ± 5.5.01 pg/ml).
As a control, we used a medium from neurons expressing
EGFP following infection with the same type of virus.
Following a 24 h Aβ treatment, we observed a significant
decrease in both SEP-GluA1 and pHuji-GluA1 fluores-
cence (Fig. 5c, d), suggesting that both recombinant
GluA1s react similarly to Aβ application. If FORTIS can
detect Aβ-induced reductions in surface AMPAR, it may
also detect drugs that prevent this effect. Thus, SEP-
GluA1-expressing neurons were exposed to a peptide
(“PTEN-PDZ”; 5 or 10 µM) that blocks the interaction of
PTEN with PDZ proteins, thereby preventing AMPAR
endocytosis and synaptic depression, rescuing cognitive
impairment in Alzheimer’s model mice17,70. We incu-
bated neurons with the peptide for 1 h at 37 °C and, after
obtaining baseline measurements, we injected freshly
prepared synthetic Aβ protofibrils (3–4 µM)17 and mea-
sured the fluorescence. The synthetic Aβ elicited a
decrease in SEP-GluA1 fluorescence (Fig. 5e, f). Yet, SEP-
GluA1 fluorescence was rescued in the cultures treated
with both Aβ and the PTEN-PDZ peptide, confirming
previous electrophysiological findings17. As Aβ assemblies
alter synaptic plasticity by inhibiting LTP in hippocampal
neurons in vitro17,79, we induced cLTP with glycine
(100 μM). In neurons treated with Aβ, we noticed a
weaker cLTP-like increase in SEP-GluA1 fluorescence,
which was partially rescued by the “PTEN-PDZ” peptide
(Fig. 5g). These findings suggest that FORTIS can detect
drugs that impede the endocytosis of AMPAR.
Discussion
This work describes the development and validation of
FORTIS, an assay to assess surface AMPARs in live
populations of primary neurons. FORTIS detects subtle
changes in surface AMPARs, including synaptic plasticity-
like changes. In addition, FORTIS is successful in detect-
ing the effects of drugs on surface AMPARs. AMPARs are
a target of interest for drug discovery and development as
they play a critical role in synaptic plasticity mechanisms
that may underlie learning and memory16,18,84,85. By
employing FORTIS and rapidly testing modulators of
AMPAR trafficking, we were able to test their effect while
avoiding the standard time-consuming experiments
required to achieve cellular or synaptic resolution. This
study represents the first attempt to use SEP-GluA1 for
the rapid, non-invasive neuronal populations’ character-
ization with a microplate reader. The addition of the new
red pH-sensitive pHuji-GluA1 reporter, combined with
instruments that integrate sensitive detectors and incu-
bation under controlled CO2, temperature, and humidity
conditions, allows us to monitor surface AMPARs over
temporal scales of seconds to days. As described here for
AMPARs, SEP or pHuji can be fused to subunits of other
receptors that control synaptic function, such as NMDA
receptors, which will enable their live monitoring in dif-
ferent populations of neurons. These features make
FORTIS compatible with studies of long-term responses to
pharmacological treatments at a high temporal resolution,
permitting cause-and-effect relationships to be deter-
mined. The length of the measurements may be extended
by using less cytotoxic viral vectors or endogenous GluA1
tagged with pH-sensitive reporters86. Since FORTIS uses a
microplate reader without imaging, its spatial resolution is
limited, and it cannot distinguish extrasynaptic from
synaptic receptors. Nevertheless, a significant advantage of
FORTIS is that it monitors thousands of neurons simul-
taneously, and, therefore, it is substantially faster than the
methods used traditionally to detect changes in AMPARs.
For example, patch-clamp recording is carried out on one
neuron at a time, while imaging can be performed on a few
dendrites and spines, considerably limiting the throughput
of these methods. Moreover, FORTIS can test dozens of
drugs simultaneously, which is impossible with traditional
approaches. In addition, and unlike the aforementioned
approaches, FORTIS does not require expertise other than
that required for culture preparation, and it does not
(see figure on previous page)
Fig. 2 Changes in SEP-GluA1 fluorescence in response to cLTP induced under different conditions. a Changes in SEP-GluA1 fluorescence
when different glycine concentrations were used for cLTP induction. b Histogram showing the ΔF/F0 (%) 35–40 min after cLTP induction with
different glycine concentrations. c Left, a heat map of the changes in SEP-GluA1 fluorescence (ΔF/F0, %) where each square represents a single
cortical culture in a 96-well plate. Right, Changes in SEP-GluA1 fluorescence when different glycine concentrations were used for induction. After the
5-min baseline, glycine was injected (indicated by the arrow), and the fluorescence was measured at 485/40–528/20 (Ex−Em) every 5 min for up to
50 min. d Frequency distribution graphs of ΔF/F0 (%) in hippocampal and cortical neurons following cLTP induction. N represents the number of
cultures. e Changes in SEP-GluA1 fluorescence after cLTP were induced with either glycine (100 μM) or Forskolin (50 μM)/Rolipram (0.1 μM). f Heat
map of the changes in SEP-GluA1 fluorescence (ΔF/F0, %) following cLTP induction (100 μM glycine) where each square represents a single
hippocampal culture prepared from either WT or Ptentg mice. g Changes in SEP-GluA1 fluorescence after cLTP was induced with glycine (100 μM) in
cultures from WT or Ptentg mice. N represents the number of cultures, and the p value was determined with two-way ANOVA, presenting the data as
the mean ± SEM.
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Fig. 3 FORTIS can detect decreases in surface GluA1 following cLTD induction. a An immunoblot showing the levels of Ser 845 phosphorylated
GluA1 or total GluA1 20 min after a 5-min exposure to different NMDA concentrations. Lower panel, in some cultures cLTD (20 μM NMDA) was
induced in the presence of the NMDA inhibitor APV (50 μM). b, c Quantification of Ser 845 phospho-GluA1 following NMDA treatment with or
without the inhibitor APV (50 μM). N represents the number of cultures, and the p value was determined with one-way ANOVA followed by Dunn’s
multiple comparison tests. d, e Changes in endogenous and recombinant (SEP-GluA1 or pHuji-GluA1) Ser 845 GluA1 phosphorylation (normalized to
vehicle) following treatment with NMDA (50 μM). N represents the number of cultures, and the p values were determined by one-way ANOVA
followed by Holm–Sidak’s multiple comparisons test. f Heat map of the changes in SEP-GluA1 fluorescence (ΔF/F0, %) where each square represents a
single cortical culture in a 96-well plate 120min after a 5-min exposure to two concentrations of NMDA, as indicated. g Changes in SEP-GluA1
fluorescence when two NMDA concentrations were used to induce cLTD. Fluorescence was measured 30 and 120min after 5-min treatment with
NMDA. N represents the number of cultures, and the p values were determined by Dunnett’s multiple comparison test, representing the data as the
mean ± SEM.
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Fig. 4 FORTIS can detect the activity of the cognitive enhancer FGL. a Heat map of SEP-GluA1 fluorescence where each square represents a single
hippocampal culture in a 96-well plate, measured following a 48 h exposure to different doses of FGL (10, 25, 50, 125, and 200 µg/ml). b Fluorescence
intensity as a function of FGL dose. c Representative immunoblots show the levels of S831 phosphorylated GluA1 in dissociated neurons treated with
different concentrations of FGL for 48 h. Actin was used as a loading control. d Quantification of pGluA1/tGluA1 following treatment with different
concentrations of FGL. e Heat map of SEP-GluA1 fluorescence measured following a 48 h exposure to FGL (25 µg/ml) in combination with TTX (3 μM) or
the PI3K inhibitor LY294002 (10 μM). f Fluorescence intensity as a function of FGL, TTX, and LY294002 treatment. N in b, d, and f represents the number of
cultures. Statistical significance in b, d, and f was calculated according to the Mann–Whitney test followed by Tukey’s multiple comparisons post hoc tests,
and the data are presented as the mean ± SEM. g, h Long-term monitoring of pHuji-GluA1 fluorescence following the administration of PD98059 (25 μM),
chelerythrine (10 μM), KN93 (20 μM), or KN92 (20 μM). The p values were determined with two-way ANOVA.
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require special equipment, such as electrophysiology set-
ups or expensive microscopes.
Together, FORTIS may provide useful measurements
for the functional screening of new synaptic modulators.
FORTIS can be used to classify neuronal responses to
multiple systematic perturbations, and it can be used in
basic science, translational research, and drug develop-
ment. For example, applying FORTIS to cell models of
Fig. 5 FORTIS can detect endocytosis induced by Aβ. a Hippocampal neurons overproducing Aβ42 due to the expression of APPswe/lnd. The medium
of these cultures that contains Aβ42 was used to induce AMPAR endocytosis in c and d. b A western blot of lysates of neurons expressing either EGFP or
APPswe/lnd and probed with an anti-β-Amyloid antibody only recognizes an APP and Aβ band in the cultures expressing APPswe/lnd. c A Heat map of SEP-
GluA1 and pHuji-GluA1 fluorescence where each square represents a single cortical culture in a 96-well plate following treatment with medium taken
from neurons expressing APPswe/lnd and secreting Aβ42 (see a). d Quantification of the experiment shown in c, showing the individual relative
fluorescence (each circle represents a single culture) following treatment with the Aβ42-containing medium. Statistical significance was calculated
according to the Mann–Whitney test. e Heat map of SEP-GluA1 relative fluorescence where each square represents a single hippocampal culture in a 96-
well plate following treatment with synthetic Aβ42 (3 or 4 μM), with or without preincubation with the PTEN-PDZ peptide (5 or 10 μM). f Quantification
of the experiment shown in e, showing the individual relative fluorescence (each circle represents a single culture) following treatment with synthetic
Aβ42 and the PTEN-PDZ peptide. Statistical significance was calculated according to the Mann–Whitney test. g cLTP was induced in cultures treated
with Aβ42 (4 μM), with or without preincubation with the PTEN-PDZ peptide (10 μM). Statistical significance was calculated according to two-way
ANOVA followed by Tukey’s multiple comparisons post hoc tests, and the data are presented as the mean ± SEM.
Calleja-Felipe et al. Translational Psychiatry          (2021) 11:324 Page 11 of 13
AD may help find novel compounds or targets that
restore aberrant synaptic function, which could serve as
the basis for new mechanism-based treatments. The
development of positive modulators of AMPARs holds
excellent promise to discover safe, effective treatments for
memory and cognitive impairments. Together, the com-
bined features of FORTIS may enhance the accessibility of
drug discovery in the neuroscience community, which
could stimulate drug discovery for neuropsychiatric
disorders.
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